*September 2020*

A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC).

A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in the subgroup of patients who received the recommended phase II dose of the drug.

No dose-limiting toxicity was observed, and grade 3/4 treatment-related adverse events (TRAEs) were manageable in most cases, reported David Hong, MD, of the University of Texas MD Anderson Cancer Center in Houston. Read more.


Support EGFR

Latest Newsletter

Get Social: Twitter